Abivax Showcases Groundbreaking Obefazimod Research Advances
Abivax Highlights Breakthrough Research on Obefazimod
In an exciting development for the treatment of ulcerative colitis (UC), Abivax, a clinical-stage biotechnology company, announced that it will present three key abstracts surrounding its lead drug candidate, obefazimod, at the prestigious UEG Week meeting. Scheduled to occur in Vienna, Austria, from October 12 to 15, 2024, this presentation aims to shed light on the latest findings from Phase 2b clinical trials.
Presentation Details at UEG Week 2024
Professor Bruce E. Sands, MD, will lead an oral presentation that discusses the efficacy and safety data collected during the maintenance phases of the obefazimod trials. The data specifically targets patients who did not respond to the initial week 8 induction therapy, showcasing its potential for those with moderately to severely active UC.
Research Insights and Key Findings
The Phase 2b study demonstrates promising outcomes from the ongoing clinical trials. Participants were closely monitored at 48 and 96 weeks, revealing significant information that supports the safety and effectiveness of obefazimod. Alongside Professor Sands' presentation, additional moderated poster sessions will highlight further data concerning corticosteroid-free efficacy results. This evidence positions obefazimod as a pivotal player in transforming treatment strategies for UC.
About Obefazimod
Obefazimod represents a novel approach in treating UC, functioning through a unique mechanism that enhances the expression of specific microRNAs. This small molecule therapy not only shows promise in alleviating symptoms for patients but may also alter the treatment landscape. Following its successful Phase 2 trials, Abivax initiated a global Phase 3 clinical trial program (ABTECT Program), marking a significant step in the pursuit of effective UC therapies.
Future Directions for Abivax
As part of its commitment to advancing gastrointestinal therapies, Abivax plans to commence a Phase 2b clinical trial in Crohn's disease in the upcoming months. This development signifies the company’s dedication to exploring the full potential of obefazimod, including potential combination therapy options tailored to improve outcomes for patients suffering from these chronic conditions.
About Abivax
Abivax is headquartered in France and the United States, focusing on utilizing natural regulatory mechanisms to bolster the immune response in chronic inflammatory diseases. Their lead investigational drug candidate, obefazimod (ABX464), is progressing through critical clinical trials aimed at offering hope to those battling UC. As Abivax continues to break new ground, further updates and corporate information can be accessed on their official website or through social media channels.
Contact Information
For inquiries, please reach out to Patrick Malloy, SVP of Investor Relations at Abivax, via email: patrick.malloy@abivax.com or call +1 847 987 4878.
Frequently Asked Questions
What is obefazimod?
Obefazimod is an investigational oral therapy designed to treat ulcerative colitis by enhancing microRNA expression.
When will the presentations occur?
The presentations will take place during the UEG Week meeting, from October 12 to October 15, 2024.
Who is presenting the findings?
Professor Bruce E. Sands will discuss the findings in an oral presentation at UEG Week.
What are the Phase 2b trial results?
The Phase 2b trials have shown promising maintenance efficacy and safety profiles for obefazimod among UC patients.
What future plans does Abivax have?
Abivax plans to initiate a Phase 2b clinical trial in Crohn's disease and continue exploring combination therapies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Tencent Music Showcases Commitment to Sustainability with ESG
- AIRAmed and Memory Treatment Centers Collaborate on Alzheimer’s Research
- Shanghai Electric Showcases Innovative Solutions at CIIF 2024
- Recent Advances in Treating Renal Impairment in Myeloma Patients
- Lam Research's Stock Surges Amid Semiconductors' Rise
- Kioxia and MoDeCH Unveil Groundbreaking 3D Probing Technology
- Molecular Partners Set to Present Groundbreaking Cancer Therapy
- Groundbreaking Schizophrenia Treatment Approved by FDA
- Canatu's Groundbreaking S-100 Reactor Aims to Transform Semiconductors
- Collaboration Between Defense Metals and Saskatchewan Research
Recent Articles
- AFL Group Showcases Strong Growth in First Half of 2024
- AKVA Group ASA Simplifies Structure Through Strategic Mergers
- Idavang A/S Calls for Extraordinary General Meeting Announcement
- Analysis of Recent Sales Trends and Market Impact
- Expliseat Launches Revolutionary Lightweight Train Seating
- Elemental Chooses ION's Aspect for Enhanced Trading Operations
- Elon Musk Questions OpenAI's Shift To For-Profit Model
- AB Science Shows Promising AB8939 Results in AML Treatment
- Sodexo Eyes Major Acquisition Opportunity with Aramark
- Treasure Play Transforms User Engagement with AI Features
- China's Journey: Celebrating 75 Years of Peace and Progress
- H&M Revises Earnings Outlook Amid Competitive Fashion Market
- BASF Adjusts Dividend Strategy with New Proposal for 2025
- Nano Dimension's Strategic Moves Propelling Stock Performance
- Virtune AB Expands Its Crypto Offerings into France with ETP
- Breakthrough Insights on AB Science’s AB8939 in AML Research
- Taiwan Stock Market Sees Gains: Key Players Making Waves
- PayPoint plc Confirms Recent Share Buyback Transaction
- Hoffmann Green Partners with Piscines Magiline for Sustainability
- Kyocera and ANREALAGE Unveil Innovative Textile Collaboration
- SEGRO plc Reports Positive Performance and Growth Strategy
- Elemental Chooses ION's Aspect for Enhanced Trading Efficiency
- YHN Acquisition I Ltd Reports Successful IPO Trust Fund
- OpenAI Restructures to Attract Investment Growth Opportunities
- Exploring Sanofi's Q3 2024 Financial Insights
- Boussard & Gavaudan Holding Limited Updates & Insights
- Boussard & Gavaudan's NAV Report: Key Insights and Updates
- Endeavour Mining's Strategic Share Buyback Initiative
- Crossject Gains Eligibility for French Investment Scheme PEA-PME
- Sampo plc's Recent Share Buyback Activity Explained
- ICAPE Group's 2024 Mid-Year Financial Results Highlights
- Join Sensorion's Upcoming Webconference for Retail Investors
- Sanofi Releases Q3 2024 Financial Aide Mémoire for Investors
- Mark Cuban and Anthony Scaramucci Criticize Gary Gensler's Policies
- Exploring China's Transformation: A Look at Progress and Change
- ValueLabs Revolutionizes Efficiency with AiDE® Transformations
- Shareholder Rights: Legal Insights for FYBR, EVBN, and SGRP
- Investigation Launched Into Revance, Gatos, and Rafael Holdings
- Focus Impact BH3 to Revise Financial Statements Amid Errors
- GeoVax Labs Expands Financing Options with New Sales Agreement
- HWH International's Debt Conversion and Market Challenges Ahead
- American Rebel Holdings Makes Strategic Financial Moves
- Investors Challenge New York's Sovereign Debt Reforms
- Navigating the New Global Financial Landscape Post-Pandemic
- Japanese Stock Market Set for Stronger Recovery in Late 2023
- Total Linhas Aereas Eyes Purchase of COMAC Aircraft for Growth
- Stellantis Embraces Low-Cost EV Strategies Amid Tariff Challenges
- Bitcoin Price Struggles Below $64k Amid Dollar Strength
- Coinweb Mainnet Launch: A New Era for Blockchain Interoperability
- SEALCOIN AG Unveils Roadmap, Whitepaper, and Future Innovations